Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Abstract

In 2030, pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer-related mortality in the world. Unfortunately, neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low. PDAC is notorious for its immune-resistant features and unique genomic landscape facilitating tumor escape from immunosurveillance. Novel immune-checkpoint inhibitors (ICI) failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials. In this paper, we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.

Keywords

Pancreatic cancer / immune-checkpoint inhibitors / tumor resistance / microenvironment

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[2] Rahib L,Aizenberg R,Fleshman JM.Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res2014;74:2913-21

[3] Von Hoff DD,Arena FP.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med2013;369:1691-703 PMCID:PMC4631139

[4] Nevala-Plagemann C,Garrido-Laguna I.From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.Nat Rev Clin Oncol2020;17:108-23

[5] Johnson DB,Moslehi JJ.Immune-checkpoint inhibitors: long-term implications of toxicity.Nat Rev Clin Oncol2022;19:254-67 PMCID:PMC8790946

[6] Shek D,Carlino MS.Immune-checkpoint inhibitors for metastatic colorectal cancer: a systematic review of clinical outcomes.Cancers2021;13:4345 PMCID:PMC8430485

[7] Shek D,Nagrial A.Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates.Oncologist2021;26:e1216-25 PMCID:PMC8265367

[8] Ho WJ,Zheng L.The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.Nat Rev Clin Oncol2020;17:527-40 PMCID:PMC7442729

[9] Akhuba L,Shek D.Where do we stand with immunotherapy for advanced pancreatic ductal adenocarcinoma: a synopsis of clinical outcomes.Biomedicines10:3196 PMCID:PMC9775646

[10] O'Reilly EM,Dhani N.Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial.JAMA Oncol2019;5:1431-8 PMCID:PMC6647002

[11] Binnewies M,Kersten K.Understanding the tumor immune microenvironment (TIME) for effective therapy.Nat Med2018;24:541-50 PMCID:PMC5998822

[12] Coppola S,Danen EHJ.A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.Drug Resist Updat2017;31:43-51

[13] Jiang H,Knolhoff BL.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Nat Med2016;22:851-60 PMCID:PMC4935930

[14] Mueller S,Maresch R.Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.Nature2018;554:62-8 PMCID:PMC6097607

[15] Stromnes IM,Hulbert A.T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma.Cancer Cell2015;28:638-52 PMCID:PMC4724422

[16] Biankin AV,Kassahn KS.Australian Pancreatic Cancer Genome InitiativePancreatic cancer genomes reveal aberrations in axon guidance pathway genes.Nature2012;491:399-405 PMCID:PMC3530898

[17] Collins MA,Zhang Y.Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.J Clin Invest2012;122:639-53 PMCID:PMC3266788

[18] El-Jawhari JJ,Scott GB.Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes.Mol Immunol2014;58:160-8

[19] Yamamoto K,Yano J.Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.Nature2020;581:100-5 PMCID:PMC7296553

[20] Rizvi NA,Snyder A.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015;348:124-8 PMCID:PMC4993154

[21] Bayne LJ,Jhala N.Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.Cancer Cell2012;21:822-35 PMCID:PMC3575028

[22] Pylayeva-Gupta Y,Hajdu CH,Bar-Sagi D.Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.Cancer Cell2012;21:836-47 PMCID:PMC3721510

[23] Lemieux E,Beaudry K,Rivard N.Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.Oncogene2015;34:4914-27 PMCID:PMC4687460

[24] Spranger S,Gajewski TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.Nature2015;523:231-5

[25] Zeng G,Micsenyi A.Aberrant Wnt/β-catenin signaling in pancreatic adenocarcinoma.Neoplasia2006;8:279-89 PMCID:PMC1600679

[26] Olive KP,Davidson CJ.Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.Science2009;324:1457-61 PMCID:PMC2998180

[27] Bear AS,O'Hara MH.Challenges and opportunities for pancreatic cancer immunotherapy.Cancer Cell2020;38:788-802 PMCID:PMC7738380

[28] Zhang J,Zajac-Kaye M.A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.Cell Cycle2014;13:3143-9 PMCID:PMC4615113

[29] Cascioferro S,Parrino B.Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.Eur J Med Chem2020;189:112088